Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy
Biomolecules and Biomedicine · 08.06.2026 · 26 (10) · 1881-1890
DOI: 10.17305/bb.2026.14167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 08.06.2026. Verfasst von Şenay Yıldırım und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Antalya Training and Research Hospital, Antalya, Türkiye. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Kidney Glomerulus, Autoantibodies. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary membranous nephropathy (pMN) is a principal cause of nephrotic syndrome in adults. The identification of the M-type phospholipase A2 receptor (PLA2R) antigen has significantly advanced non-invasive management; however, the precise clinical relationship between circulating antibody titers and intrarenal antigen deposition continues to be debated. This single-center retrospective study sought to analyze the correlation between clinicopathological parameters, serum anti-PLA2R levels, and glomerular PLA2R tissue expression in pMN. A specific focus was placed on evaluating the diagnostic utility of tissue staining in seronegative patients. A cohort of 49 adult pMN patients, diagnosed via renal biopsy between 2018 and 2025, was evaluated. Serum anti-PLA2R antibodies were quantified using ELISA, while glomerular PLA2R expression and staining intensity (graded 0 to +3) were assessed via immunohistochemistry (IHC) on paraffin-embedded sections. The results demonstrated a notable discordance: the overall serum antibody positivity rate was 49.0%, yet tissue PLA2R expression was detected in 100% of the cohort, encompassing all seronegative cases. A statistically significant difference was observed in the distribution of tissue PLA2R staining intensity based on serum PLA2R status (p=0.002). Conversely, no statistically significant correlation was found between circulating antibody titers and baseline renal function or proteinuria markers (p>0.05). In conclusion, these findings indicate that negative serology does not preclude tissue PLA2R positivity, potentially attributable to mechanisms such as the "kidney-as-a-sink" phenomenon or persistent immunological footprints. This investigation underscores that serum and tissue PLA2R serve as complementary, rather than mutually exclusive, markers. Consequently, renal biopsy with supplementary IHC staining remains a crucial and clinically valuable diagnostic tool, particularly in seronegative cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Antalya Training and Research Hospital, Antalya, Türkiye.
- Department of Internal Medicine, Division of Nephrology, Akdeniz University Faculty of Medicine, Antalya, Türkiye.
- Department of Internal Medicine, Antalya City Hospital, Antalya, Türkiye.
- Department of Internal Medicine, Serik State Hospital, Antalya, Türkiye.
- Department of Internal Medicine, Division of Nephrology, The University of Health Sciences, Antalya Training and Research Hospital, Antalya, Türkiye.
Zitieren
APA
Yıldırım, Ş., İnci, A., Karaduru Avcı, A., Koç, L. Z., Nergiz, D., & Yılmaz, Ü. (2026). Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy. Biomolecules and Biomedicine, 26(10), 1881-1890. https://doi.org/10.17305/bb.2026.14167
Vancouver
Yıldırım Ş, İnci A, Karaduru Avcı A, Koç LZ, Nergiz D, Yılmaz Ü. Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy. Biomolecules and Biomedicine. 2026;26(10):1881-1890. doi:10.17305/bb.2026.14167
BibTeX
@article{Yldrm2026,
author = {Yıldırım, Şenay and İnci, Ayça and Karaduru Avcı, Ayşe and Koç, Lütfullah Zahit and Nergiz, Döndü and Yılmaz, Üstün},
title = {Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy},
journal = {Biomolecules and Biomedicine},
year = {2026},
volume = {26},
number = {10},
pages = {1881--1890},
doi = {10.17305/bb.2026.14167}
}
EUVIMED